Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Paragon Capital Management Inc.

Paragon Capital Management Inc. cut its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 25.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,309 shares of the biopharmaceutical company's stock after selling 18,030 shares during the quarter. Royalty Pharma accounts for about 1.3% of Paragon Capital Management Inc.'s investment portfolio, making the stock its 18th largest holding. Paragon Capital Management Inc.'s holdings in Royalty Pharma were worth $1,628,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP boosted its holdings in shares of Royalty Pharma by 417.6% during the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares during the period. Sanctuary Advisors LLC lifted its position in Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after purchasing an additional 388 shares during the last quarter. Truist Financial Corp bought a new stake in Royalty Pharma in the 4th quarter valued at about $371,000. Illinois Municipal Retirement Fund grew its position in Royalty Pharma by 39.3% in the 4th quarter. Illinois Municipal Retirement Fund now owns 131,615 shares of the biopharmaceutical company's stock worth $3,357,000 after purchasing an additional 37,136 shares during the last quarter. Finally, Bryn Mawr Capital Management LLC increased its stake in shares of Royalty Pharma by 7.1% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 9,100 shares of the biopharmaceutical company's stock valued at $232,000 after purchasing an additional 600 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analysts Forecast Growth

RPRX has been the topic of a number of recent analyst reports. Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 price objective on the stock. Wall Street Zen upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research report on Saturday, June 21st. Finally, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $47.33.

Royalty Pharma Trading Down 1.8%

NASDAQ:RPRX opened at $35.27 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.56 and a quick ratio of 1.56. The stock has a market cap of $19.83 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 1.84 and a beta of 0.48. The stock's 50-day moving average is $33.40 and its two-hundred day moving average is $31.48. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $36.32.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.07. The firm had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. As a group, equities research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were issued a dividend of $0.22 per share. The ex-dividend date was Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.50%. Royalty Pharma's dividend payout ratio is 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.